Willie A Deese
CIK 1328766 · Exe V-P & Pres. MMD · last filed 2026-05-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
13320 BALLANTYNE CORPORATE PLACE
CHARLOTTE, NC 28277
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PEG | Director | 11,933 | $70.32 | $839.1K | $0 | 12 | 2026-05-05 |
| XRAY | Director | 57,748 | $8.42 | $486.2K | -$510.1K | 53 | 2026-01-13 |
| CDK Global, Inc. (CDK) Delisted | Director | 0 | $54.76 | $0 | $0 | 9 | 2022-07-06 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 14,389 | $7.15 | $102.9K | $0 | 5 | 2022-06-24 |
| MRK | Exe V-P & Pres. MMD | 134,478 | $143.63 | $19.32M | -$19.64M | 37 | 2016-02-24 |
Recent Filings · Page 2 of 15
142 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-15 | XRAY | Grant (A) | +51 | $0 | EDGAR |
| 2024-05-24 | XRAY | Grant (A) | +7,994 | $0 | EDGAR |
| 2024-05-02 | PEG | Grant (A) | +2,579 | $180.0K | EDGAR |
| 2024-04-15 | XRAY | Grant (A) | +26 | $0 | EDGAR |
| 2024-01-16 | XRAY | Grant (A) | +21 | $0 | EDGAR |
| 2023-10-16 | XRAY | Grant (A) | +48 | $0 | EDGAR |
| 2023-07-17 | XRAY | Grant (A) | +41 | $0 | EDGAR |
| 2023-05-26 | XRAY | Grant (A) | +5,419 | $0 | EDGAR |
| 2023-05-02 | PEG | Grant (A) | +2,851 | $180.0K | EDGAR |
| 2023-04-18 | XRAY | Grant (A) | +22 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.